MedTrace Logo

A Phase Ia Safety and Tolerability Study of BL-001

NCT05818306 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2023-06-27

No results posted yet for this study

Summary

To investigate the safety and tolerability of BL-001 in healthy volunteers for 28 consecutive days.

Conditions

  • Healthy Volunteers

Interventions

DRUG

BL-001

Live biological product BL-001

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Bloom Science

    lead INDUSTRY

Principal Investigators

  • Paolo Baroldi · Bloom Science

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-20
Primary Completion
2023-05-19
Completion
2023-06-02

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05818306 on ClinicalTrials.gov